The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.
 
Jorge Hernando-Cubero
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai; Ipsen; Novartis; Pfizer; Sanofi
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; Genzyme; IPSEN; Lexicon; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Roche
Consulting or Advisory Role - Ipsen; MSD; Pfizer
Research Funding - AstraZeneca (Inst); Ipsen (Inst); MTEM/Threshold (Inst); Pfizer (Inst); Roche
 
Daniel E. Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Toni Ibrahim
No Relationships to Disclose
 
Nicola Fazio
Honoraria - Ipsen; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Merck Serono; MSD Oncology; Novartis/Ipsen; Pfizer
Research Funding - Merck Serono (Inst); Novartis (Inst)
 
Carlos Lopez
Consulting or Advisory Role - Ipsen; Merck; Novartis; Pfizer; Sanofi
Research Funding - Ipsen; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen; Merck
 
Alex Teule
No Relationships to Disclose
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; AstraZeneca (I); Boehringer Ingelheim (I); BRISTOL-MYERS SQUIBB; Bristol-Myers Squibb (I); Gilead Sciences (I); Ipsen; Lilly (I); MERCK; Merck (I); NOVARTIS; PFIZER; PharmaMar; PharmaMar (I); ROCHE; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer
Speakers' Bureau - Ipsen; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck; Roche
 
Marc Diez
No Relationships to Disclose
 
Daniel Acosta
No Relationships to Disclose
 
Maria Roca
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer